Lack of effects on male fertility from a quadrivalent HPV vaccine in Sprague-Dawley rats

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 89, Issue 5, 2010, Pages 376-381

  Wise, L David ^a   Pauley, Cindy J ^a   Michael, Bindhu ^a   Wolf, Jayanthi J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fertility; HPV; Human papillomavirus; Quadrivalent HPV vaccine; Reproductive performance; Sperm assessment; Vaccine

Indexed keywords

VIRUS ANTIBODY; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; AUTOPSY; CESAREAN SECTION; COITUS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GESTATIONAL AGE; HISTOLOGY; IMMUNOGENICITY; MALE; MALE FERTILITY; NONHUMAN; PRIORITY JOURNAL; RAT; REPRODUCTION; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY;

ALPHAPAPILLOMAVIRUS; ANIMALS; ANTIBODIES, VIRAL; EPIDIDYMIS; FEMALE; FERTILITY; MALE; PAPILLOMAVIRUS VACCINES; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCTION; SPERM MOTILITY; TESTIS;

HUMAN PAPILLOMAVIRUS; RATTUS;

EID: 78650435531     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20259     Document Type: Article

References (18)

1. Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS. 2010. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Ped Inf Dis J 29:1-7.
2. Cates Jr W. 1999. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 26(Suppl):S2-S7.
3. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta analysis. Br J Cancer 88:63-73.
4. Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, Cunningham ML. 2009. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 114:1170-1178.
5. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. 2006. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis 194:1044-1057.
6. FDA. 2006. Guidance for Industry. Considerations for developmental toxicity studies for prevention and therapeutic vaccines for infectious disease indications.
7. FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915-1927.
8. Garland SM, Hernandez-Avila M, Wheeler CM, et al. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928-1943.
9. Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, Zhou H, Haupt RM, Garner EI, Quadrivalent Human Papillomavirus Vaccine Phase III Investigators. 2009. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine. Obstetrics and Gynecology 114:1179-1188.
10. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagnostic Lab Immun 10:108-115.
11. ®: Prophylactic human papillomavirus vaccine development: from bench top to bed-side. Clin Pharm Therapeut 81:259-264.
12. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. 2009. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302:750-757.
13. Tucker ME. 2009. HPV vaccine shows efficacy in males. Family Pract News 39:1.
14. Verdier F, Barrow PC, Burge J. 2003. Reproductive toxicity testing of vaccines. Toxicology 185:213-219.
15. Villa LL, Costa RLR, Petta CA, et al. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278.
16. Villa LL, Ault KA, Giuliano AR, et al. 2006. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24:5571-5583.
17. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki B, Fukumoto L. 2002. External genital warts: Diagnosis, treatment and prevention. Clin Infect Dis 35:S210-S224.
18. Wise LD, Wolf JJ, Kaplanski CV, Pauley CJ, Ledwith BJ. 2008. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats. Birth Defects Res B Dev Reprod Toxicol 83:561-572.